Cibus (NASDAQ:CBUS) Releases Earnings Results

Cibus (NASDAQ:CBUS) posted its quarterly earnings results on Thursday. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.10), FiscalAI reports. Cibus had a negative return on equity of 200.87% and a negative net margin of 2,366.33%.The business had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $1.70 million.

Here are the key takeaways from Cibus’ conference call:

• Revenue increased 35% year to date to $2.7 million, driven by Sustainable Ingredients collaboration agreements, while R&D and SG&A expenses declined by nearly $5 million year over year.
• Cibus expects additional scale-up orders for its biofragrance program in the second half of 2026 and estimates a potential $20 million–$40 million annual revenue opportunity when fully commercialized.
• The company pushed its expected initial Latin American rice commercialization from late 2027 to 2028; U.S. commercialization remains targeted for 2029, and royalties are not expected to begin until 2028.
• Cibus highlighted expanding rice partnerships, including Interoc’s increase from two traits to five, and described a potential rice royalty opportunity exceeding $200 million annually at peak adoption across the Americas.
• Cibus had $20.4 million in cash at June 30 and expects funding only into early Q1 2027, while its projected annualized net cash usage exiting 2026 increased to approximately $35 million as it invests in technology and personnel.

Cibus Trading Up 0.5%

Cibus stock traded up $0.01 during trading on Thursday, reaching $1.90. The company had a trading volume of 240,835 shares, compared to its average volume of 455,177. The firm has a market capitalization of $145.03 million, a price-to-earnings ratio of -0.96 and a beta of 1.61. The firm’s 50-day simple moving average is $1.63 and its 200 day simple moving average is $1.97. Cibus has a 52 week low of $1.09 and a 52 week high of $4.19.

Analysts Set New Price Targets

A number of research firms have commented on CBUS. Weiss Ratings downgraded shares of Cibus from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 29th. Wall Street Zen raised Cibus from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $9.00.

Institutional Trading of Cibus

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its stake in Cibus by 4.7% in the 4th quarter. Geode Capital Management LLC now owns 275,180 shares of the company’s stock worth $479,000 after buying an additional 12,467 shares in the last quarter. Raymond James Financial Inc. lifted its position in shares of Cibus by 31.0% in the second quarter. Raymond James Financial Inc. now owns 53,713 shares of the company’s stock valued at $74,000 after acquiring an additional 12,722 shares in the last quarter. PACK Private Wealth LLC bought a new position in shares of Cibus in the fourth quarter worth about $27,000. Bank of America Corp DE boosted its stake in shares of Cibus by 113.4% in the fourth quarter. Bank of America Corp DE now owns 35,536 shares of the company’s stock worth $99,000 after acquiring an additional 18,885 shares during the period. Finally, Goldman Sachs Group Inc. grew its position in shares of Cibus by 60.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 52,364 shares of the company’s stock worth $91,000 after purchasing an additional 19,717 shares in the last quarter. Hedge funds and other institutional investors own 33.81% of the company’s stock.

Cibus Company Profile

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.